JUL 22, 2021 12:00 PM EDT

Genetic engineering approaches to support clinical applications of T-cell receptor libraries targeting oncogenic mutations

C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract

T-cells targeting shared oncogenic mutations can induce durable tumor regression in epithelial cancer patients. Such T cells can be detected in tumor-infiltrating lymphocytes and peripheral blood of patients with the common metastatic epithelial cancers. In recent years, we and others have worked toward developing libraries of T-cell receptors targeting oncogenic mutations such as KRAS and TP53. Such T-cell receptor libraries offer an opportunity to treat patients with autologous or allogeneic T-cells genetically engineered to express selected T-cell receptors. Although attractive, such clinical application of T-cell receptor libraries should be accompanied by innovative genetic engineering platforms allowing cheaper, faster, and more flexible manufacturing solutions. This talk will discuss the methods to isolate, clone, and validate T-cell receptors targeting oncogenic mutations, the therapeutic potential of such libraries, and the genetic engineering platforms currently used for clinical manufacturing. We will also address the genetic engineering tools needed to allow such an approach to become widely and commercially applicable.

Learning Objectives:

1. Discuss methods to isolate, clone, and validate T-cell receptors targeting oncogenic mutations.

2. Define the therapeutic potential of TCR libraries targeting oncogenic mutations.

3. Indicate the current and future genetic engineering platforms needed to support clinical applications using off-the-shelf TCR libraries.


Show Resources
You May Also Like
FEB 24, 2021 10:00 AM PST
C.E. CREDITS
FEB 24, 2021 10:00 AM PST
DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
MAR 30, 2021 8:00 AM PDT
MAR 30, 2021 8:00 AM PDT
DATE: March 30, 2021 TIME: 08:00am PST In this talk, we will discuss the value of moving towards modular and automated, closed-system technologies designed to enable scalable and cost-effect...
APR 21, 2021 10:00 AM PDT
C.E. CREDITS
APR 21, 2021 10:00 AM PDT
Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
APR 07, 2021 9:00 AM PDT
C.E. CREDITS
APR 07, 2021 9:00 AM PDT
One challenge pharmaceutical companies face, is moving promising biotherapeutic products into the clinic as fast as safely possible. Devoting the correct amount of time and resources to earl...
C.E. CREDITS
Parkinson’s disease (PD) is the second most common neurodegenerative disorder with multiple motor and non-motor symptoms. PD is characterized by the presence on proteinaceous neuronal...
Loading Comments...
Show Resources